Shield Therapeutics (LON:STX) Trading Down 10% - What's Next?

Key Points

• Shield Therapeutics shares fell by 10% during mid-day trading, dropping from a previous close of GBX 9 ($0.12) to GBX 8.10 ($0.11).
• The company has a market capitalization of £83.49 million and a significantly high debt-to-equity ratio of 3,691.50.
• Shield Therapeutics specializes in pharmaceuticals, delivering Accrufer® to address iron deficiency, with its product recently launched in the U.S.

Shield Therapeutics plc (LON:STX - Get Free Report) dropped 10% on Monday . The company traded as low as GBX 7.70 ($0.10) and last traded at GBX 8.10 ($0.11). Approximately 8,309,130 shares traded hands during trading, an increase of 202% from the average daily volume of 2,753,942 shares. The stock had previously closed at GBX 9 ($0.12).

Analyst Upgrades and Downgrades

Separately, Peel Hunt reaffirmed a "buy" rating and set a GBX 15 price objective on shares of Shield Therapeutics in a research report on Monday. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Shield Therapeutics has an average rating of "Buy" and a consensus price target of GBX 15.

Shield Therapeutics Stock Performance

The stock's fifty day moving average price is GBX 5.92 and its 200-day moving average price is GBX 3.80. The company has a market capitalization of £82.17 million, a P/E ratio of -394.40 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.